1. AF.51 VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE MANAGEMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE. (September 2021) Authors: Macaluso, F.S.; Cappello, M.; Crispino, F.; Grova, M.; Privitera, A.C.; Piccillo, G.; Magnano, A.; Ferracane, C.; Belluardo, N.; Giangreco, E.; Fries, W.; Viola, A.; Di Mitri, R.; Mocciaro, F.; Camilleri, S.; Garufi, S.; Renna, S.; Casà, A.; Maida, M.; Orlando, A. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AF.57 SPOSAB ABP 501: A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501. (September 2021) Authors: Macaluso, F.S.; Cappello, M.; Busacca, A.; Fries, W.; Viola, A.; Costantino, G.; Magnano, A.; Vinci, E.; Ferracane, C.; Privitera, A.C.; Piccillo, G.; Belluardo, N.; Giangreco, E.; Romano, C.; Citrano, M.; Graziano, F.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Scrivo, B. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OC.12.1 SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2. (1st October 2020) Authors: Macaluso, F.S.; Fries, W.; Viola, A.; Centritto, A.; Cappello, M.; Giuffrida, E.; Privitera, A.C.; Piccillo, G.; Magnano, A.; Vinci, E.; Vassallo, R.; Trovatello, A.; Belluardo, N.; Giangreco, E.; Camilleri, S.; Garufi, S.; Bertolami, C.; Ventimiglia, M.; Renna, S.; Orlando, R. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 2 Page Start: S37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗